Antigen-based immunotherapy (AIT) for autoimmune and allergic disease

Macleod, M. K.L. and Anderton, S. M. (2015) Antigen-based immunotherapy (AIT) for autoimmune and allergic disease. Current Opinion in Pharmacology, 23, pp. 11-16. (doi: 10.1016/j.coph.2015.05.003) (PMID:26004365)

108330.pdf - Published Version
Available under License Creative Commons Attribution.



Autoimmune and allergic diseases are major causes of morbidity. Antigen-based immunotherapy (AIT) is immunologically the most satisfying means of specifically targeting only those T cells driving disease, thereby inducing antigen-specific immune tolerance, with the lowest adverse risk profile. AIT is highly effective in rodent models of T cell-driven inflammation and is now in clinical trials. The range of approaches to applying AIT in the clinic prevents a consensus on the molecular basis for this form of tolerance. In particular, there has been a paucity of information on how pre-activated effector and memory T cells respond to AIT. New, advanced murine models of AIT are beginning to deliver such information at the cellular, biochemical, transcriptional and epigenetic levels.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Macleod, Dr Megan
Authors: Macleod, M. K.L., and Anderton, S. M.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Current Opinion in Pharmacology
Publisher:Elsevier Ltd.
ISSN (Online):1471-4973
Copyright Holders:Copyright © 2015 The Authors
First Published:First published in Current Opinion in Pharmacology 23:11-16
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record